HopeStage
Back to all studies
CompletedNCT02978599

AVL-3288 for Schizophrenia: A Placebo-Controlled Crossover Study

About this titleRead the official source — NCT02978599
Medication studyAges 18–50United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
New YorkSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2016
Recruitment status
Completed
Enrollment listed in the registry
24
Sponsor
New York State Psychiatric Institute
Sponsor type
Research institute
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 50 Years
Official registry ID
NCT02978599
Official title
Show the full official title

Double Blind, Two Dose, Cross-over Clinical Trial of the Positive Allosteric Modulator at the alpha7 Nicotinic Cholinergic Receptor AVL-3288 in Schizophrenia Patients

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

New York

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is New York State Psychiatric Institute, a research institute.

Did this study involve medication?

Yes. The study involved medication, including AVL-3288 and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies